Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PT-199 by Phanes Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PT-199 is under clinical development by Phanes Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Data Insights
PT-199 by Phanes Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PT-199 is under clinical development by Phanes Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...